SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics.
"Murali is a digital transformation leader with 25 years of experience designing and implementing technology strategy in the healthcare, financial services and transportation industries," said Mr. Davis. "He brings deep expertise in leading high-performance global teams and steering the design and delivery of large-scale, complex technology solutions. I'm pleased to welcome Murali to the Quest team."
Prior to joining Quest, Murali was Chief Information Officer at Oak Street Health, which was acquired by CVS Health in 2023. Prior to Oak Street, Murali was Chief Information Officer for Card Services at Fiserv and has also held IT leadership roles at JPMorgan Chase Bank and General Electric.
Mr. Balakumar earned a bachelor's degree in engineering from the Indian Institute of Technology in Chennai, India; a master's in engineering from the University of Texas; and an MBA from the University of Chicago.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of deidentified clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.
Last Trade: | US$163.36 |
Daily Change: | 0.89 0.55 |
Daily Volume: | 864,266 |
Market Cap: | US$18.230B |
January 08, 2025 December 03, 2024 October 23, 2024 October 22, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load